Granata A V, Hillman A L
Yale School of Medicine, New Haven, Connecticut, USA.
Ann Intern Med. 1998 Jan 1;128(1):56-63. doi: 10.7326/0003-4819-128-1-199801010-00009.
In this paper, cost and effectiveness data for six clinical interventions are applied simultaneously to a hypothetical population of 100,000 patients to show how selecting guidelines to maximize overall population benefit compares with selecting the best guidelines for individual patients. By entering effectiveness (added survival) and cost information from recent prevention, screening, diagnostic, and therapeutic guidelines into a computer-based optimization model, the options that maximized overall population effectiveness while keeping additional cost within varying specified constraints were identified. In 57% of selection opportunities, the clusters of guidelines that yielded maximum population benefit differed from those that maximized benefit for individual patients. Some choices were more stable than others over ranges of cost constraints. Clinical practice guidelines chosen to maximize cost-effectiveness for individual patients often do not maximize cost-effectiveness for populations of patients. To allocate resources as efficiently as possible, decision makers should consider other sources of information in addition to the recommendations of specific practice guidelines. "Robust" guidelines that simultaneously address both individual and societal health benefit should be sought.
在本文中,六种临床干预措施的成本和效果数据被同时应用于一个10万患者的假设群体,以展示选择使总体人群受益最大化的指南与为个体患者选择最佳指南相比有何不同。通过将近期预防、筛查、诊断和治疗指南中的效果(增加的生存期)和成本信息输入基于计算机的优化模型,确定了在将额外成本控制在不同指定约束范围内的同时使总体人群效果最大化的选项。在57%的选择机会中,产生最大人群受益的指南组合与使个体患者受益最大化的指南组合不同。在成本约束范围内,一些选择比其他选择更稳定。为使个体患者的成本效益最大化而选择的临床实践指南通常并不能使患者群体的成本效益最大化。为了尽可能有效地分配资源,决策者除了特定实践指南的建议外,还应考虑其他信息来源。应寻求同时兼顾个体和社会健康效益的“稳健”指南。